Thomas Zhang
About Thomas Zhang
Thomas Zhang is a Research Associate at the Broad Institute of MIT and Harvard, where he focuses on cancer treatment resistance mechanisms. He also serves as the Founder and President of Aldercare and has a background in Biological Sciences from the University of Pittsburgh.
Work at Broad Institute
Thomas Zhang has been employed at the Broad Institute of MIT and Harvard as a Research Associate since 2019. In this role, he focuses on understanding the mechanisms of resistance in cancer treatments through the use of computational tools. His work contributes to the broader mission of the institute, which is to advance the understanding of human disease and improve health outcomes.
Previous Research Experience
Prior to his current position, Thomas Zhang worked as an Undergraduate Researcher at the University of Pittsburgh from 2016 to 2019. He was involved in research for three years, focusing on various aspects of biological sciences. Additionally, he served as a Student Researcher at Stevens Institute of Technology for one year, from 2014 to 2015, where he gained foundational research experience in a collaborative academic environment.
Education in Biological Sciences
Thomas Zhang earned a Bachelor of Science degree in Biological Sciences from the University of Pittsburgh, completing his studies from 2015 to 2019. His education provided him with a solid foundation in biological principles, which he applies in his current research endeavors, particularly in cancer biology.
Leadership at Aldercare
In addition to his research roles, Thomas Zhang is the Founder and President of Aldercare, a position he has held since 2018. Based in Pittsburgh, PA, Aldercare focuses on initiatives related to health and wellness. His leadership role demonstrates his commitment to translating research into practical applications that can benefit the community.
Research Focus and Aspirations
Thomas Zhang's research primarily focuses on validating novel cancer drivers through functional experiments. He aspires to bridge the gap between bench lab research and clinical treatments as a physician scientist, aiming to enhance the effectiveness of cancer therapies and improve patient outcomes.